After a year of treatment, tesamorelin didn't show a clear improvement in muscle energy recovery compared to a placebo in obese people with low growth hormone.

Pro

Against

Evidence from Studies

Supporting (0)

Community contributions welcome

No supporting evidence found

Contradicting (1)

Community contributions welcome

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Randomized Controlled Trial

Human

2014 Jan

Even though the average improvement in muscle energy recovery wasn’t dramatically different between the drug and placebo groups, people who got the drug and had higher IGF-I levels showed much better muscle recovery — meaning the drug likely helped, but the study didn’t highlight this connection in the claim.

Source Study

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Score: 61

DOI: 10.1210/jc.2013-3436

Similar Assertions

Even though the drug raised IGF-I levels, it didn’t make the muscle energy recovery noticeably better than the placebo — so the effect might be subtle or only show up in certain people.

89%

In obese people with low growth hormone taking tesamorelin, the link between higher IGF-I and better muscle energy recovery is even stronger than in the whole study group.

88%

In obese people with low growth hormone taking tesamorelin, the link between higher IGF-I and better muscle energy recovery is even stronger than in the whole group of participants.

87%

In people who took tesamorelin, the more their IGF-I levels went up, the better their muscles recovered after exercise — and this link was even stronger than in the whole group.

81%

Even when researchers removed blurry or low-quality scans, the link between IGF-I and muscle energy recovery stayed strong — so the finding is reliable.

81%